To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
All the news of the Institute of life sciences Frédéric Joliot
Europe | European ＆ international partnerships | Chemistry | Radiobiology
HORIZON EUROPE - MSCA
The main objective of the ISOBIOTICS project is to fund the PhDs (three or four years) of 11 early-career researchers in the field of isotope labeling of biological drugs, and provide them with a dual academic and industrial culture to meet the needs of industry.
The ISOBIOTICS project, coordinated by Dr. Christophe Dugave at CEA (SCBM/DMTS), aims to develop new approaches for the isotopic labeling of biological drugs such as peptides, proteins, oligonucleotides and analogues, with 2H/3H, 13C/14C and 18F through the training of talented young chemists between 2023 and 2027. Fellows will prepare a PhD in 3 or 4 years (depending on their university of affiliation). ISOBIOTICS: a new strategy for the isotopic labeling of biological drugs Recent years have seen the clinical introduction of bio-drugs such as peptides, proteins and oligonucleotides, due to their specificity and low toxicity compared to chemical drugs. Analysis of the pharmacokinetics of these bio-drugs requires the incorporation of radioisotopes to trace their distribution in the body. The radiolabeling of biopharmaceuticals represents a major challenge. However, radiolabeling of biopharmaceuticals represents a major challenge, and in order to reduce their immunogenicity, overcome their fragility and increase their ability to reach their target, it is mainly small-scale biologics that are being developed. The ambition of the ISOBIOTICS project is therefore to develop a new radiolabeling strategy adapted to these particular molecules to i) advance research and development into biotherapies that are more effective in terms of targeting and less immunogenic, and ii) train a new generation of radiochemists with a dual academic and industrial culture who will implement these methods to meet the needs of European industry. Objectives and ambitions : - Develop new, chemically harmless strategies for late-stage radiolabeling of large peptides, small to medium-sized proteins, oligonucleotides and analogues with deuterium, tritium, carbon-14 (phase 0 preclinical and clinical evaluation) and fluorine-18 (phase I-III clinical trials). - Train a new generation of talented young PhD students specializing in radiolabeling of bio-products through a combination of interdisciplinary laboratory research, cross-disciplinary and cross-industry secondments, technical courses, scientific conferences and complementary skills workshops. - Ensure the appropriate dissemination, exploitation and communication of all ISOBIOTICS results to maximize the project's impact and influence - Guarantee the employment of students and the sustainability of training structures
Joliot institute contact : Christophe Dugave (firstname.lastname@example.org)
- Websites https://www.isobiotics-project.org/ - https://cordis.europa.eu/project/id/101072780
ISOBIOTICS official video- ISOBIOTICS Newsletter n°1 (summer 2023)
Objective of Doctoral
Networks (DN, ex ITN)Implement doctoral programmes by partnerships of
organisations from different sectors across Europe and beyond to train highly
skilled doctoral candidates, stimulate their creativity, enhance their
innovation capacities and boost their employability in the long-term.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.